drugset / Trial / NCT03601871
The Efficacy and Safety of Thalidomide in Preventing CINV Induced by Cisplatin-containing Chemotherapy
RandomizedParallel-groupOpen-labelPrevention
Summary
This is a pragmatic randomized, multi-center, open-label randomized clinical trial, aimed to evaluate efficacy and safety of thalidomide in improving prevention of chemotherapy-induced delayed nausea and vomiting (CINV) in chemotherapy-naive patients after multi-cycle cisplatin-containing highly emetogenic chemotherapy (HEC) .
Timeline
- Start
- 2018-07-12
- Primary completion
- 2020-06-30
- Completion
- 2020-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Thalidomide | Other / unclassified | 100 mg | Oral |
| Background | Dexamethasone | Small molecule | 8 mg | Oral |
| Background | Palonosetron | Other / unclassified | 0.25 mg | Intravenous |